geh200520
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2022 (NCT05629689)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06398730 | Phase 1 | Jul 2, 2024 | Fortrea, General Electric, PPD |
| NCT05629689 | Phase 1 | Dec 1, 2022 | General Electric |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| General Electric | For profit | 2 | 2 | 1 | 2022 |
| Fortrea | For profit | 1 | 0 | 1 | 2024 |
| PPD | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1